Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT — Stella

Recruiting

Back to B-cell Acute Lymphoblastic Leukemia trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Children's Hospital of Wisconsin, Milwaukee, Wisconsin

Key details

Phase

Safety & dosing

Sponsor

Medical College of Wisconsin

Collaborators

Amgen, University of Wisconsin, Madison

Enrollment target

~25 participants

Started

February 2021

Primary completion

February 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Last updated September 2021

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov